These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36692387)

  • 21. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
    N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasoconstrictors in hepatorenal syndrome - A critical review.
    Mattos ÂZ; Schacher FC; Mattos AA
    Ann Hepatol; 2019; 18(2):287-290. PubMed ID: 31023616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of terlipressin in critically ill children with liver disease.
    Saxena R; Anand A; Deep A
    BMC Nephrol; 2020 Aug; 21(1):360. PubMed ID: 32819297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1.
    Velez JCQ; Karakala N; Tayebi K; Wickman TJ; Mohamed MMB; Kovacic RA; Therapondos G; Kanduri SR; Allegretti AS; Belcher JM; Regner KR; Wentowski C
    Kidney360; 2023 Apr; 4(4):e448-e456. PubMed ID: 36763632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the role for terlipressin in hepatorenal syndrome?
    Bass SN; Kapoor A; Lindenmeyer CC
    Cleve Clin J Med; 2023 Nov; 90(11):664-667. PubMed ID: 37914199
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.
    Moore K; Jamil K; Verleger K; Luo L; Kebede N; Heisen M; Corman S; Leonardi R; Bakker R; Maï C; Shamseddine N; Huang X; Allegretti AS
    Aliment Pharmacol Ther; 2020 Jul; 52(2):351-358. PubMed ID: 32495956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].
    Xing F; Li S; Zhang JJ; Sun CY; Huang JR; Gao ZL; Zhu TT; Zhao Q; Zhang H; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):982-988. PubMed ID: 31941260
    [No Abstract]   [Full Text] [Related]  

  • 28.  Hepatorenal syndrome: Current concepts related to diagnosis and management.
    de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
    Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
    Ripoll C; Platzer S; Franken P; Aschenbach R; Wienke A; Schuhmacher U; Teichgräber U; Stallmach A; Steighardt J; Zipprich A;
    Trials; 2023 Apr; 24(1):258. PubMed ID: 37020315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatorenal syndrome in the era of acute kidney injury.
    Solé C; Pose E; Solà E; Ginès P
    Liver Int; 2018 Nov; 38(11):1891-1901. PubMed ID: 29845739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy.
    Velez JCQ
    Kidney360; 2022 Feb; 3(2):382-395. PubMed ID: 35373127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study.
    Kulkarni AV; Ravikumar ST; Tevethia H; Premkumar M; Kumar K; Sharma M; Gupta R; Rao PN; Reddy DN
    Sci Rep; 2022 Apr; 12(1):5503. PubMed ID: 35365736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.
    Bai Z; An Y; Guo X; Teschke R; Méndez-Sánchez N; Li H; Qi X
    Can J Gastroenterol Hepatol; 2020; 2020():5106958. PubMed ID: 32676484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
    Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
    Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study.
    Saif RU; Dar HA; Sofi SM; Andrabi MS; Javid G; Zargar SA
    Indian J Gastroenterol; 2018 Sep; 37(5):424-429. PubMed ID: 30178092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatorenal syndrome in patients with cirrhosis.
    Moreau R
    J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia.
    Rey R M; Delgado AF; De Zubiria A; Pinto R; De la Hoz-Valle JA; Pérez-Riveros ED; Ardila G; Sierra-Arango F
    PLoS One; 2020; 15(10):e0239834. PubMed ID: 33079947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.